Pharmaceutical

GSK and CureVac restructure mRNA vaccine development deal

GSK and CureVac have announced the restructuring of their existing partnership into a new licensing agreement for mRNA vaccine candidates.

Jul 4, 2024 - 04:00
GSK and CureVac restructure mRNA vaccine development deal
GSK and CureVac have announced the restructuring of their existing partnership into a new licensing agreement for mRNA vaccine candidates.
Read the original article

Tags:

Previous Article

EMA approves Sanofi’s Dupixent for COPD treatment in adults

Next Article

Protecting your drug products: Strategies for preventing metal contamination in ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BGBA-3055 by BeiGene for Solid Tumor: Likelihood of App...

Oct 3, 2023

Can the government ask social media sites to take down Covid misinformation? SCOTUS will weigh in

Can the government ask social media sites to take down ...

Jan 30, 2024

Silence announces $120m private placement for depositary shares

Silence announces $120m private placement for depositar...

Feb 6, 2024